Cited by 39Epigenetics and DNA MethylationCell death mechanisms and regulationCancer-related Molecular Pathways

Inhibition of DNA methylation promotes breast tumor sensitivity to netrin‐1 interference

Open access
Grandin, Mélodie, Mathot, Pauline, Devailly, Guillaume, Bidet, Yannick, Ghantous, Akram, Favrot, Clementine, Gibert, Benjamin, Gadot, Nicolas +6 more·2016·EMBO Molecular Medicine

Abstract

In a number of human cancers, NTN1 upregulation inhibits apoptosis induced by its so-called dependence receptors DCC and UNC5H, thus promoting tumor progression. In other cancers however, the selective inhibition of this dependence receptor death pathway relies on the silencing of pro-apoptotic effector proteins. We show here that a substantial fraction of human breast tumors exhibits simultaneous DNA methylation-dependent loss of expression of NTN1 and of DAPK1, a serine threonine kinase known to transduce the netrin-1 dependence receptor pro-apoptotic pathway. The inhibition of DNA methylation by drugs such as decitabine restores the expression of both NTN1 and DAPK1 in netrin-1-low cancer cells. Furthermore, a combination of decitabine with NTN1 silencing strategies or with an anti-netrin-1 neutralizing antibody potentiates tumor cell death and efficiently blocks tumor growth in different animal models. Thus, combining DNA methylation inhibitors with netrin-1 neutralizing agents may be a valuable strategy for combating cancer.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.15252/emmm.201505945

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 48 · Cited by 39

Authors
Grandin, M., Mathot, P., Devailly, G., Bidet, Y., Ghantous, A., Favrot, C., Gibert, B., Gadot, N., Puisieux, I., Herceg, Z., Delcros, J., Bernet, A., Mehlen, P., & Dante, R.
Affiliations
  • Centre National de la Recherche Scientifique (FR)
  • Centre Jean Perrin (FR)
  • Centre international de recherche sur le cancer (FR)
  • Université de Lyon (FR)
  • Lyon 1 Université (FR)
Corresponding author
  • Mehlen, Patrick
  • Dante, Robert
Venue
EMBO Molecular Medicine
Published
2016-07-04
Volume
8
Issue
8
Pages
863-877
ISSN
  • 1757-4676 (ISSN-L)
  • 1757-4684
OpenAlex
W2474707695
Cited by
39
References
48
Citations by year
2026: 4 · 2025: 5 · 2024: 2 · 2023: 4 · 2022: 6 · 2021: 2 · 2020: 4 · 2019: 5 · 2018: 3 · 2017: 3 · 2016: 1
FWCI
2.08
Type
journal article
Language
en
Open access
Locations
  • EMBO Molecular Medicine (publishedVersion, other-oa)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, cc-by)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by)
  • HAL (submittedVersion, cc-by-nc)
  • HAL (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, cc-by)
  • Zurich Open Repository and Archive (University of Zurich) (submittedVersion, cc-by)
  • Zurich Open Repository and Archive (University of Zurich)
Funders
  • CNRS
  • University of Lyon
  • Centre Léon Bérard
  • Ligue Contre le Cancer
  • INCA
  • ANR
  • ERC
  • Fondation Bettencourt
  • LabEx DEVweCAN
  • EU‐FP7
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Keywords
netrin-1, DNA methylation, DAPK1, dependence receptors, DCC, decitabine, epigenetic silencing, apoptosis, breast cancer, combination therapy, tumor growth inhibition
MeSH terms
Netrin-1, Breast Neoplasms, Humans, Nerve Growth Factors, Down-Regulation, Cell Death, DNA Methylation, Tumor Suppressor Proteins, Cell Line, Tumor, Death-Associated Protein Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review